Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8489101 | 1.00 | NR1H2 (0.60) | NR1H2PTPN1HDAC8MMP8MMP3 | |
| SCHEMBL18264880 | 0.88 | PTPN1 (0.68) | NR1H2PTPN1HDAC8MMP8MMP3 | |
| SCHEMBL6397202 | 0.88 | PTPN1 (0.68) | NR1H2PTPN1HDAC8MMP8MMP3 | |
| SCHEMBL6393250 | 0.87 | PTPN1 (0.69) | NR1H2PTPN1HDAC8 | |
| SCHEMBL19460728 | 0.86 | PTPN1 (0.54) | PTPN1HDAC8POLB | |
| SCHEMBL29502321 | 0.86 | PTPN1 (0.54) | PTPN1HDAC8 | |
| SCHEMBL864823 | 0.86 | PTPN1 (0.54) | PTPN1HDAC8 | |
| SCHEMBL19460727 | 0.86 | PTPN1 (0.54) | PTPN1HDAC8POLB | |
| SCHEMBL29773931 | 0.86 | PTPN1 (0.54) | PTPN1HDAC8 | |
| SCHEMBL30254985 | 0.86 | PTPN1 (0.54) | PTPN1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170157265-A1 | ISOQUINOLIDINOBENZODIAZEPINES | CELLERANT THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP | 2013-11-14 | — | — | US | disclosed |
| US-8513433-B2 | Small molecule inhibitors of PARP activity | ANGION BIOMEDICA CORP. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2011002520-A2 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157265-A1 | ISOQUINOLIDINOBENZODIAZEPINES | BCR, IGLV6-57, GABRA4 | NR1H2 2989/4885PTPN1 2714/4885HDAC8 585/4885 |
| US-20130303567-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | NR1H2 2770/4885PTPN1 4744/4885HDAC8 605/4885 |
| US-20120184533-A1 | SMALL MOLECULE INHIBITORS OF PARP ACTIVITY | PARP1, PARP11, PARP15 | NR1H2 2770/4885PTPN1 4744/4885HDAC8 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.